Third quarter revenue of $712 million; (17)% reported growth
Pro forma* total revenue of $1,033 million; 9% pro forma non-COVID organic growth
Third quarter GAAP EPS from continuing operations of $0.55; pro forma adjusted EPS of $1.51
Initiates fourth quarter and updates full year pro forma guidance

PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 2, 2022.

The Company reported GAAP earnings per share from continuing operations of $0.55, as compared to GAAP earnings per share from continuing operations of $0.94 in the same period a year ago. GAAP revenue for the quarter was $712 million, as compared to $861 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $111 million, as compared to $196 million for the same period a year ago. GAAP operating profit margin was 15.6% as a percentage of revenue, as compared to 22.7% in the same period a year ago.

Adjusted operating income from continuing operations was $224 million, as compared to $322 million for the same period a year ago. Adjusted operating profit margin was 31.4% as a percentage of revenue, as compared to 37.4% in the same period a year ago.

Pro forma adjusted earnings per share for the quarter was $1.51, as compared to $2.31 in the same period a year ago. Pro forma adjusted revenue for the quarter was $1.03 billion, as compared to $1.17 billion in the same period a year ago. Pro forma adjusted operating income for the quarter was $272 million, as compared to $359 million for the same period a year ago. Pro forma adjusted operating profit margin was 26.3% as a percentage of adjusted revenue, as compared to 30.8% in the same period a year ago.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

*Pro forma information includes results from the Applied, Food and Enterprise Services ("AES") businesses currently held for sale.

"It was great to see how we continued to execute at a high level across the company in the quarter, both operationally and financially," said Prahlad Singh, president and chief executive officer of PerkinElmer. "The energy and excitement amongst our employees in all our businesses remains exceptional as we continue to prepare for the upcoming split into two separate companies. I am proud to see the impact our efforts are having on society and how we accomplish this each day."

Financial Overview by Reporting Segment for the Third Quarter

Discovery & Analytical Solutions Continuing Operations

Third quarter 2022 revenue was $313 million, as compared to $208 million in the same period a year ago. Reported revenue increased 51% and organic revenue increased 14% as compared to the same period a year ago.
Third quarter 2022 operating income from continuing operations was $33 million, as compared to $(19) million for the same period a year ago.
Third quarter 2022 adjusted operating income was $117 million, as compared to $58 million for the same period a year ago.

Discovery & Analytical Solutions Pro Forma* Operations

Third quarter 2022 pro forma revenue was $633 million, as compared to $513 million in the same period a year ago. Pro forma revenue increased 23% and pro forma organic revenue increased 12% as compared to the same period a year ago.
Third quarter 2022 pro forma operating income was $58 million, as compared to $7 million for the same period a year ago.
Third quarter 2022 pro forma adjusted operating income was $165 million, as compared to $95 million for the same period a year ago.

Diagnostics

Third quarter 2022 revenue was $399 million, as compared to $654 million for the same period a year ago. Reported revenue decreased 39% and organic revenue decreased 33% as compared to the same period a year ago.
Third quarter 2022 operating income from continuing operations was $95 million, as compared to $238 million for the same period a year ago.
Third quarter 2022 adjusted operating income was $123 million, as compared to $287 million for the same period a year ago.

Initiates Fourth Quarter and Updates Full Year 2022 Guidance

For the fourth quarter of 2022, the Company forecasts total revenue from continuing operations of $0.73 billion. Pro forma total revenue is expected to be in a range of approximately $1.06-$1.07 billion and pro forma adjusted earnings per share are expected to be in a range $1.65-$1.67.

For the full year 2022, the Company now forecasts total revenue from continuing operations of $3.30 billion. Pro forma total revenue is expected to be in the range of approximately $4.59-$4.60 billion and pro forma adjusted earnings per share are expected to be in a range of $7.89-$7.91.

The Company's guidance for the fourth quarter and full year with respect to non-GAAP metrics cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its third quarter 2022 results and its outlook for business trends during a webcast on November 8, 2022, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, www.perkinelmer.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates", "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, such as the divestiture of the Applied, Food and Enterprise Services businesses, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) the United Kingdom's withdrawal from the European Union; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) discontinuation or replacement of LIBOR; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS

	Three Months Ended						Nine Months Ended
(In thousands, except per share data)	October 2, 2022			October 3, 2021			October 2, 2022			October 3, 2021


Revenue	$	711,803		$	861,316		$	2,570,608		$	2,799,898

Cost of revenue		304,759			338,454			1,017,108			1,009,707
Selling, general and administrative expenses		239,969			275,869			765,746			681,311
Research and development expenses		53,521			49,421			167,081			139,753
Restructuring and other, net		2,774			2,011			15,443			10,517

Operating income from continuing operations		110,780			195,561			605,230			958,610

Interest income		(667	)		(544	)		(2,024	)		(1,322	)
Interest expense		25,931			43,531			81,447			74,407
Change in fair value of financial securities		5,106			19,365			14,321			(8,566	)
Other (income) expense, net		(1,732	)		(1,803	)		(1,904	)		(9,787	)

Income from continuing operations, before income taxes		82,142			135,012			513,390			903,878

Provision for income taxes		12,634			27,381			98,211			198,531

Income from continuing operations		69,508			107,631			415,179			705,347

Income from discontinued operations, before income taxes		25,180			26,656			36,004			64,329
Provision for income taxes on discontinued operations and dispositions		9,341			6,549			9,662			16,703

Income from discontinued operations and dispositions		15,839			20,107			26,342			47,626

Net income	$	85,347		$	127,738		$	441,521		$	752,973


*Diluted earnings per share:*
Income from continuing operations	$	0.55		$	0.94		$	3.28		$	6.23

Income from discontinued operations and dispositions		0.13			0.17			0.21			0.42

Net income	$	0.67		$	1.11		$	3.49		$	6.65


Weighted average diluted shares of common stock outstanding		126,540			115,022			126,544			113,307

ABOVE PREPARED IN ACCORDANCE WITH GAAP

Additional Supplemental Information ⁽¹⁾:
(per share, continuing operations)

GAAP EPS from continuing operations	$	0.55		$	0.94		$	3.28		$	6.23
Amortization of intangible assets		0.72			0.55			2.22			1.40
Gain from debt extinguishment		(0.00	)		-			(0.00	)		-
Purchase accounting adjustments		0.08			0.09			0.36			0.17
Acquisition and divestiture-related costs		0.07			0.61			0.20			0.64
Change in fair value of financial securities		0.04			0.17			0.11			(0.08	)
Asset impairment		-			0.03			-			0.03
Significant litigation matters and settlements		0.00			-			(0.00	)		-
Disposition of businesses and assets, net		-			(0.02	)		-			(0.02	)
Restructuring and other, net		0.02			0.02			0.12			0.09
Tax on above items		(0.24	)		(0.31	)		(0.77	)		(0.49	)
Significant tax items		(0.03	)		(0.01	)		(0.03	)		0.12
Adjusted EPS from Continuing Operations	$	1.21		$	2.07		$	5.50		$	8.10

Adjusted EPS from AES	$	0.30		$	0.24		$	0.75		$	0.74

Pro Forma Adjusted EPS including the results of AES	$	1.51		$	2.31		$	6.24		$	8.84

*(1) amounts may not sum due to rounding*

PerkinElmer, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)

			Three Months Ended						Nine Months Ended
(In thousands, except percentages)			October 2, 2022			October 3, 2021			October 2, 2022			October 3, 2021


DAS	Reported revenue	$	312,783		$	207,511		$	945,484		$	577,371
	Purchase accounting adjustments		-			-			-			1,849
	Adjusted revenue		312,783			207,511			945,484			579,220

	Reported operating income (loss) from continued operations		32,631			(19,263	)		106,005			50,624
	OP%		10.4	%		-9.3	%		11.2	%		8.8	%
	Amortization of intangible assets		64,426			25,757			185,094			50,903
	Purchase accounting adjustments		9,164			5,673			43,710			9,322
	Acquisition and divestiture-related costs		8,475			44,409			11,746			46,498
	Significant litigation matters and settlements		629			-			(632	)		-
	Restructuring and other, net		1,556			1,424			11,738			6,867
	Adjusted operating income		116,881			58,000			357,661			164,214
	Adjusted OP%		37.4	%		28.0	%		37.8	%		28.4	%

Diagnostics	Reported revenue		399,020			653,805			1,625,124			2,222,527
	Purchase accounting adjustments		203			199			609			597
	Adjusted revenue		399,223			654,004			1,625,733			2,223,124

	Reported operating income from continued operations		94,654			237,903			553,898			965,650
	OP%		23.7	%		36.4	%		34.1	%		43.4	%
	Amortization of intangible assets		27,099			37,517			95,375			107,743
	Purchase accounting adjustments		457			5,107			1,884			9,485
	Asset impairment		-			3,868			-			3,868
	Acquisition and divestiture-related costs		-			2,023			14,119			7,833
	Restructuring and other, net		1,218			587			3,705			3,650
	Adjusted operating income		123,428			287,005			668,981			1,098,229
	Adjusted OP%		30.9	%		43.9	%		41.1	%		49.4	%

Corporate	Reported operating loss		(16,505	)		(23,079	)		(54,673	)		(57,664	)

Continuing Operations	Reported revenue	$	711,803		$	861,316		$	2,570,608		$	2,799,898
	Purchase accounting adjustments		203			199			609			2,446
	Adjusted revenue		712,006			861,515			2,571,217			2,802,344

	Reported operating income from continued operations		110,780			195,561			605,230			958,610
	OP%		15.6	%		22.7	%		23.5	%		34.2	%
	Amortization of intangible assets		91,525			63,274			280,469			158,646
	Purchase accounting adjustments		9,621			10,780			45,594			18,807
	Acquisition and divestiture-related costs		8,475			46,432			25,865			54,331
	Asset impairment		-			3,868			-			3,868
	Significant litigation matters and settlements		629			-			(632	)		-
	Restructuring and other, net		2,774			2,011			15,443			10,517
	Adjusted operating income	$	223,804		$	321,926		$	971,969		$	1,204,779
	Adjusted OP%		31.4	%		37.4	%		37.8	%		43.0	%

REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

			Three Months Ended						Nine Months Ended
(In thousands, except percentages)			October 2, 2022			October 3, 2021			October 2, 2022			October 3, 2021


DAS	Reported revenue	$	312,783		$	207,511		$	945,484		$	577,371
	Purchase accounting adjustments		-			-			-			1,849
	Adjusted revenue		312,783			207,511			945,484			579,220

	Reported operating income from continued operations		32,631			(19,263	)		106,005			50,624
	OP%		10.4	%		-9.3	%		11.2	%		8.8	%
	Amortization of intangible assets		64,426			25,757			185,094			50,903
	Purchase accounting adjustments		9,164			5,673			43,710			9,322
	Acquisition and divestiture-related costs		8,475			44,409			11,746			46,498
	Significant litigation matters and settlements		629			-			(632	)		-
	Restructuring and other, net		1,556			1,424			11,738			6,867
	Adjusted operating income		116,881			58,000			357,661			164,214
	Adjusted OP%		37.4	%		28.0	%		37.8	%		28.4	%

AES Discontinued Operations	Revenue in Discontinued Ops		320,616			305,369			950,822			902,946

	Reported operating income in discontinued operations		25,389			26,409			36,642			63,624
	OP%		7.9	%		8.6	%		3.9	%		7.0	%
	Amortization of intangible assets		2,387			7,680			16,984			26,026
	Acquisition and divestiture-related costs		22,026			2,651			47,042			15,066
	Restructuring and other, net		486			200			13,131			2,501
	Pro-Forma deprecation on assets held for sale		(2,363	)		-			(2,363	)		-
	Adjusted operating income of AES		47,925			36,940			111,436			107,217
	Adjusted OP%		14.9	%		12.1	%		11.7	%		11.9	%

Pro Forma DAS	Revenue including AES		633,399			512,880			1,896,306			1,480,317
	Purchase accounting adjustments		-			-			-			1,849
	Adjusted revenue including AES		633,399			512,880			1,896,306			1,482,166

	Operating income including AES		58,020			7,146			142,647			114,248
	OP%		9.2	%		1.4	%		7.5	%		7.7	%
	Amortization of intangible assets		66,813			33,437			202,078			76,929
	Purchase accounting adjustments		9,164			5,673			43,710			9,322
	Acquisition and divestiture-related costs		30,501			47,060			58,788			61,564
	Significant litigation matters and settlements		629			-			(632	)		-
	Restructuring and other, net		2,042			1,624			24,869			9,368
	Pro-Forma deprecation on assets held for sale		(2,363	)		-			(2,363	)		-
	Adjusted operating income including AES		164,806			94,940			469,097			271,431
	Adjusted OP%		26.0	%		18.5	%		24.7	%		18.3	%

Diagnostics	Reported revenue		399,020			653,805			1,625,124			2,222,527
	Purchase accounting adjustments		203			199			609			597
	Adjusted revenue		399,223			654,004			1,625,733			2,223,124

	Reported operating income from continued operations		94,654			237,903			553,898			965,650
	OP%		23.7	%		36.4	%		34.1	%		43.4	%
	Amortization of intangible assets		27,099			37,517			95,375			107,743
	Purchase accounting adjustments		457			5,107			1,884			9,485
	Asset impairment		-			3,868			-			3,868
	Acquisition and divestiture-related costs		-			2,023			14,119			7,833
	Restructuring and other, net		1,218			587			3,705			3,650
	Adjusted operating income		123,428			287,005			668,981			1,098,229
	Adjusted OP%		30.9	%		43.9	%		41.1	%		49.4	%

Corporate	Reported operating loss		(16,505	)		(23,079	)		(54,673	)		(57,664	)

Pro Forma Operating Results including AES	Revenue including AES	$	1,032,419		$	1,166,685		$	3,521,430		$	3,702,844
	Purchase accounting adjustments		203			199			609			2,446
	Adjusted revenue including AES		1,032,622			1,166,884			3,522,039			3,705,290

	Operating income including AES		136,169			221,970			641,872			1,022,234
	OP%		13.2	%		19.0	%		18.2	%		27.6	%
	Amortization of intangible assets		93,912			70,954			297,453			184,672
	Purchase accounting adjustments		9,621			10,780			45,594			18,807
	Acquisition and divestiture-related costs		30,501			49,083			72,907			69,397
	Asset impairment		-			3,868			-			3,868
	Significant litigation matters and settlements		629			-			(632	)		-
	Restructuring and other, net		3,260			2,211			28,574			13,018
	Pro-Forma deprecation on assets held for sale		(2,363	)		-			(2,363	)		-
	Adjusted operating income including AES	$	271,729		$	358,866		$	1,083,405		$	1,311,996
	Adjusted OP%		26.3	%		30.8	%		30.8	%		35.4	%

REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

*(1) amounts may not sum due to rounding*

PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)	October 2, 2022		January 2, 2022

Current assets:
Cash and cash equivalents	$	400,741	$	603,320
Accounts receivable, net		540,867		707,941
Inventories, net		378,256		425,890
Other current assets		138,867		148,255
Current assets of discontinued operations		1,657,749		555,374
Total current assets		3,116,480		2,440,780

Property, plant and equipment, net		460,397		485,531
Operating lease right-of-use assets		160,120		164,040
Intangible assets, net		3,401,143		3,821,847
Goodwill		6,373,327		6,627,119
Other assets, net		312,297		312,887
Long-term assets of discontinued operations		-		1,148,350
Total assets	$	13,823,764	$	15,000,554

Current liabilities:
Current portion of long-term debt	$	503,549	$	4,240
Accounts payable		275,824		324,811
Accrued expenses and other current liabilities		471,570		728,445
Current liabilities of discontinued operations		234,788		156,248
Total current liabilities		1,485,731		1,213,744

Long-term debt		3,898,267		4,979,737
Long-term liabilities		1,231,724		1,413,196
Operating lease liabilities		142,842		147,395
Long-term liabilities of discontinued operations		-		105,237
Total liabilities		6,758,564		7,859,309

Total stockholders' equity		7,065,200		7,141,245
Total liabilities and stockholders' equity	$	13,823,764	$	15,000,554


PREPARED IN ACCORDANCE WITH GAAP

PerkinElmer, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS


	Three Months Ended						Nine Months Ended
	October 2, 2022			October 3, 2021			October 2, 2022			October 3, 2021
	(In thousands)						(In thousands)

Operating activities:
Net income	$	85,347		$	127,738		$	441,521		$	752,973
Income from discontinued operations and dispositions, net of income taxes		(15,839	)		(20,107	)		(26,342	)		(47,626	)
Income from continuing operations		69,508			107,631			415,179			705,347
Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:
Stock-based compensation		10,112			5,835			39,776			16,718
Restructuring and other, net		2,774			2,011			15,443			10,517
Depreciation and amortization		104,736			76,146			322,766			197,386
Change in fair value of contingent consideration		(2,132	)		1,076			(769	)		1,553
Amortization of deferred debt financing costs and accretion of discounts		2,194			1,500			6,046			3,224
Change in fair value of financial securities		5,106			19,365			14,321			(8,566	)
Debt extinguishment income		(580	)		-			(92	)		-
Amortization of acquired inventory revaluation		11,315			9,425			45,039			14,728
Gain on disposition of businesses and assets, net		-			(1,970	)		-			(1,970	)
Asset impairment		-			3,868			-			3,868
Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:
Accounts receivable, net		28,637			87,718			93,092			224,162
Inventories		(19,996	)		7,796			(61,632	)		14,683
Accounts payable		(16,429	)		(9,358	)		(24,314	)		(40,009	)
Accrued expenses and other		(72,496	)		(20,787	)		(338,223	)		(168,949	)
Net cash provided by operating activities of continuing operations		122,749			290,256			526,632			972,692
Net cash provided by operating activities of discontinued operations		37,205			23,539			14,020			102,466
Net cash provided by operating activities		159,954			313,795			540,652			1,075,158

Investing activities:
Capital expenditures		(13,095	)		(26,365	)		(59,502	)		(59,066	)
Purchases of investments		(17,765	)		(4,623	)		(45,010	)		(19,130	)
Proceeds from notes receivables		8,890			-			8,890			-
Proceeds from disposition of businesses and assets		4,610			1,460			5,664			1,460
Cash paid for acquisitions, net of cash acquired		(1,884	)		(3,264,981	)		(7,768	)		(3,967,678	)
Net cash used in investing activities of continuing operations		(19,244	)		(3,294,509	)		(97,726	)		(4,044,414	)
Net cash used in investing activities of discontinued operations		(3,263	)		(6,419	)		(9,441	)		(8,393	)
Net cash used in investing activities		(22,507	)		(3,300,928	)		(107,167	)		(4,052,807	)

Financing Activities:
Payments on borrowings		-			(427,580	)		(220,000	)		(1,191,125	)
Proceeds from borrowings		-			415,282			220,000			1,144,282
Payments of term loan		(50,000	)		-			(500,000	)		-
Proceeds from term loan		-			500,000			-			500,000
Payments of senior debt		(7,472	)		-			(7,472	)		(339,605	)
Proceeds from sale of senior debt		-			2,286,239			-			3,086,095
Payments of debt financing costs		-			(22,741	)		-			(30,983	)
Settlement of cash flow hedges		-			4,477			(762	)		(1,459	)
Net payments on other credit facilities		343			(905	)		(487	)		(12,731	)
Proceeds from issuance of common stock under stock plans		413			8,575			6,254			22,760
Purchases of common stock		(89	)		(89	)		(56,137	)		(73,013	)
Dividends paid		(8,835	)		(7,842	)		(26,502	)		(23,539	)
Net cash (used in) provided by financing activities of continuing operations		(65,640	)		2,755,416			(585,106	)		3,080,682
Net cash (used in) provided by financing activities of discontinued operations		-			-			-			-
Net cash (used in) provided by financing activities		(65,640	)		2,755,416			(585,106	)		3,080,682

Effect of exchange rate changes on cash, cash equivalents, and restricted cash		(17,427	)		(5,925	)		(51,404	)		(16,584	)

Net increase (decrease) in cash, cash equivalents, and restricted cash		54,380			(237,642	)		(203,025	)		86,449
Cash, cash equivalents, and restricted cash at beginning of period		361,932			726,704			619,337			402,613
Cash, cash equivalents, and restricted cash at end of period	$	416,312		$	489,062		$	416,312		$	489,062


Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents	$	400,741		$	472,374		$	400,741		$	472,374
Restricted cash included in other current assets		284			1,689			284			1,689
Restricted cash included in other assets		288			-			288			-
Cash and cash equivalents included in current assets of discontinued operations		14,999			14,999			14,999			14,999
Total cash, cash equivalents and restricted cash	$	416,312		$	489,062		$	416,312		$	489,062

PREPARED IN ACCORDANCE WITH GAAP

PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

(In millions, except per share data and percentages)	PKI
	Three Months Ended
	October 2, 2022					October 3, 2021
Adjusted revenue:
Revenue	$	711.8				$	861.3
Purchase accounting adjustments		0.2					0.2
Adjusted revenue	$	712.0				$	861.5

Adjusted gross margin:
Gross margin	$	407.0		57.2	%	$	522.9		60.7	%
Amortization of intangible assets		35.3		5.0	%		28.5		3.3	%
Purchase accounting adjustments		11.7		1.6	%		9.6		1.1	%
Acquisition and divestiture-related costs		1.5		0.2	%		-		0.0	%
Adjusted gross margin	$	455.5		64.0	%	$	560.9		65.1	%

Adjusted SG&A:
SG&A	$	240.0		33.7	%	$	275.9		32.0	%
Amortization of intangible assets		(56.2	)	-7.9	%		(34.8	)	-4.0	%
Purchase accounting adjustments		2.1		0.3	%		(1.2	)	-0.1	%
Acquisition and divestiture-related costs		(5.7	)	-0.8	%		(46.4	)	-5.4	%
Asset impairment		-		0.0	%		(3.9	)	-0.4	%
Significant litigation matters and settlements		(0.6	)	-0.1	%		-		0.0	%
Adjusted SG&A	$	179.6		25.2	%	$	189.6		22.0	%

Adjusted R&D:
R&D	$	53.5		7.5	%	$	49.4		5.7	%
Purchase accounting adjustments		(0.1	)	0.0	%		-		0.0	%
Acquisition and divestiture-related costs		(1.3	)	-0.2	%		-		0.0	%
Adjusted R&D	$	52.2		7.3	%	$	49.4		5.7	%

Adjusted operating income:
Operating income	$	110.8		15.6	%	$	195.6		22.7	%
Amortization of intangible assets		91.5		12.9	%		63.3		7.3	%
Purchase accounting adjustments		9.6		1.4	%		10.8		1.3	%
Acquisition and divestiture-related costs		8.5		1.2	%		46.4		5.4	%
Asset impairment		-		0.0	%		3.9		0.4	%
Significant litigation matters and settlements		0.6		0.1	%		-		0.0	%
Restructuring and other, net		2.8		0.4	%		2.0		0.2	%
Adjusted operating income	$	223.8		31.4	%	$	321.9		37.4	%

	PKI
	Three Months Ended
	October 2, 2022					October 3, 2021
Adjusted EPS:
GAAP EPS	$	0.67				$	1.11
Discontinued operations, net of income taxes		0.13					0.17
GAAP EPS from continuing operations		0.55					0.94
Amortization of intangible assets		0.72					0.55
Debt extinguishment costs		(0.00	)				-
Purchase accounting adjustments		0.08					0.09
Acquisition and divestiture-related costs		0.07					0.61
Change in fair value of financial securities		0.04					0.17
Asset impairment		-					0.03
Significant litigation matters and settlements		0.00					-
Disposition of businesses and assets, net		-					(0.02	)
Restructuring and other, net		0.02					0.02
Tax on above items		(0.24	)				(0.31	)
Significant tax items		(0.03	)				(0.01	)
Adjusted EPS	$	1.21				$	2.07

GAAP EPS from discontinued operations		0.13					0.17
Amortization of intangible assets included in discontinued operations		0.02					0.07
Acquisition and divestiture-related costs included in discontinued operations		0.17					0.02
Restructuring and other, net included in discontinued operations		0.00					0.00
Pro Forma depreciation expense on assets held for sale		(0.02	)				-
Tax on above items		(0.00	)				(0.02	)
Less non-AES income tax items in discontinued operations		0.00					0.00
Adjusted EPS from AES	$	0.30				$	0.24

Pro Forma Adjusted EPS including the results of AES	$	1.51				$	2.31

	DAS
	Three Months Ended
	October 2, 2022					October 3, 2021

Revenue	$	312.8				$	207.5

Adjusted operating income:
Operating income	$	32.6		10.4	%	$	(19.3	)	-9.3	%
Amortization of intangible assets		64.4		20.6	%		25.8		12.4	%
Purchase accounting adjustments		9.2		2.9	%		5.7		2.7	%
Acquisition and divestiture-related costs		8.5		2.7	%		44.4		21.4	%
Significant litigation matters and settlements		0.6		0.2	%		-		0.0	%
Restructuring and other, net		1.6		0.5	%		1.4		0.7	%
Adjusted operating income	$	116.9		37.4	%	$	58.0		28.0	%

	Diagnostics
	Three Months Ended
	October 2, 2022					October 3, 2021
Adjusted revenue:
Revenue	$	399.0				$	653.8
Purchase accounting adjustments		0.2					0.2
Adjusted revenue	$	399.2				$	654.0

Adjusted operating income:
Operating income	$	94.7		23.7	%	$	237.9		36.4	%
Amortization of intangible assets		27.1		6.8	%		37.5		5.7	%
Purchase accounting adjustments		0.5		0.1	%		5.1		0.8	%
Asset impairment		-		0.0	%		3.9		0.6	%
Acquisition and divestiture-related costs		-		0.0	%		2.0		0.3	%
Restructuring and other, net		1.2		0.3	%		0.6		0.1	%
Adjusted operating income	$	123.4		30.9	%	$	287.0		43.9	%

*(1) amounts may not sum due to rounding*

PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

(In millions, except per share data and percentages)	PKI
	Nine Months Ended
	October 2, 2022					October 3, 2021
Adjusted revenue:
Revenue	$	2,570.6				$	2,799.9
Purchase accounting adjustments		0.6					2.4
Adjusted revenue	$	2,571.2				$	2,802.3

Adjusted gross margin:
Gross margin	$	1,553.5		60.4	%	$	1,790.2		63.9	%
Amortization of intangible assets		107.1		4.2	%		64.3		2.3	%
Purchase accounting adjustments		46.1		1.8	%		17.2		0.6	%
Acquisition and divestiture-related costs		4.7		0.2	%		-		0.0	%
Adjusted gross margin	$	1,711.3		66.6	%	$	1,871.7		66.8	%

Adjusted SG&A:
SG&A	$	765.7		29.8	%	$	681.3		24.3	%
Amortization of intangible assets		(173.4	)	-6.7	%		(94.3	)	-3.4	%
Purchase accounting adjustments		0.6		0.0	%		(1.6	)	-0.1	%
Acquisition and divestiture-related costs		(17.1	)	-0.7	%		(54.3	)	-1.9	%
Asset impairment		-		0.0	%		(3.9	)	-0.1	%
Significant litigation matters and settlements		0.6		0.0	%		-		0.0	%
Adjusted SG&A	$	576.5		22.4	%	$	527.1		18.8	%

Adjusted R&D:
R&D	$	167.1		6.5	%	$	139.8		5.0	%
Purchase accounting adjustments		(0.2	)	0.0	%		-		0.0	%
Acquisition and divestiture-related costs		(4.1	)	-0.2	%		-		0.0	%
Adjusted R&D	$	162.8		6.3	%	$	139.8		5.0	%

Adjusted operating income:
Operating income	$	605.2		23.5	%	$	958.6		34.2	%
Amortization of intangible assets		280.5		10.9	%		158.6		5.7	%
Purchase accounting adjustments		45.6		1.8	%		18.8		0.7	%
Acquisition and divestiture-related costs		25.9		1.0	%		54.3		1.9	%
Asset impairment		-		0.0	%		3.9		0.1	%
Significant litigation matters and settlements		(0.6	)	0.0	%		-		0.0	%
Restructuring and other, net		15.4		0.6	%		10.5		0.4	%
Adjusted operating income	$	972.0		37.8	%	$	1,204.8		43.0	%

	PKI
	Nine Months Ended
	October 2, 2022					October 3, 2021
Adjusted EPS:
GAAP EPS	$	3.49				$	6.65
Discontinued operations		0.21					0.42
GAAP EPS from continuing operations		3.28					6.23
Amortization of intangible assets		2.22					1.40
Debt extinguishment costs		(0.00	)				-
Purchase accounting adjustments		0.36					0.17
Acquisition and divestiture-related costs		0.20					0.64
Change in fair value of financial securities		0.11					(0.08	)
Asset impairment		-					0.03
Significant litigation matters and settlements		(0.00	)				-
Disposition of businesses and assets, net		-					(0.02	)
Restructuring and other, net		0.12					0.09
Tax on above items		(0.77	)				(0.49	)
Significant tax items		(0.03	)				0.12
Adjusted EPS	$	5.50				$	8.10

GAAP EPS from discontinued operations		0.21					0.42
Amortization of intangible assets included in discontinued operations		0.13					0.23
Acquisition and divestiture-related costs included in discontinued operations		0.37					0.13
Restructuring and other, net included in discontinued operations		0.10					0.02
Pro Forma depreciation expense on assets held for sale		(0.02	)				-
Tax on above items		(0.05	)				(0.06	)
Less non-AES income tax items in discontinued operations		0.00					0.00
Adjusted EPS from AES	$	0.75				$	0.74

Pro forma adjusted EPS including the results of AES	$	6.24				$	8.84

	PKI
	Three Months Ended					Twelve Months Ended
	January 1, 2023					January 1, 2023
Pro forma adjusted revenue:	*Projected*					*Projected*
GAAP revenue from continuing operations	$	730				$	3,300
AES revenue		330 - 340				1,290 - 1,300
Pro forma adjusted revenue	$1,060 - $1,070					$4,590 $4,600

	DAS
	Nine Months Ended
	October 2, 2022					October 3, 2021

Revenue	$	945.5				$	577.4

Adjusted operating income:
Operating income	$	106.0		11.2	%	$	50.6		8.8	%
Amortization of intangible assets		185.1		19.6	%		50.9		8.8	%
Purchase accounting adjustments		43.7		4.6	%		9.3		1.6	%
Acquisition and divestiture-related costs		11.7		1.2	%		46.5		8.1	%
Significant litigation matters and settlements		(0.6	)	-0.1	%		-		0.0	%
Restructuring and other, net		11.7		1.2	%		6.9		1.2	%
Adjusted operating income	$	357.7		37.8	%	$	164.2		28.4	%

	Diagnostics
	Nine Months Ended
	October 2, 2022					October 3, 2021
Adjusted revenue:
Revenue	$	1,625.1				$	2,222.5
Purchase accounting adjustments		0.6					0.6

PerkinElmer Announces Financial Results for the Third Quarter of 2022